Monday, Pfizer-BioNTech Announce Reached an agreement with a United Nations-backed medical supply group to expand its production of COVID-19 antiviral pills. While poorer countries are still struggling to obtain similar virus vaccination opportunities, the new agreement will expand access to COVID-19 treatment.
According to the agreement, Pfizer Agreed to grant a license for antiviral drugs to the Geneva Medicine Patent Pool, a public health organization supported by the United Nations. After the announcement, Pfizer CEO Albert Bourla stated that his company is pleased to be able to contribute to relief efforts in countries where COVID-19 treatment is difficult.
“Pfizer remains committed to bringing scientific breakthroughs to help everyone end this pandemic. We believe that oral antiviral therapy can play an important role in reducing the severity of COVID-19 infection, reducing the pressure on our healthcare system, and saving lives. Role,” Bourla said.
“We must work hard to ensure that everyone-no matter where they live or the environment-can get these breakthroughs, and we are very happy to be able to work with MPP to further advance our commitment to fairness.”
Charles Gore, the executive director of MPP, described Pfizer pills as “very suitable for low- and middle-income countries” and will play an important role in the fight against the virus.
According to the agreement, Pfizer and the countries that will benefit from the transaction have some restrictions. For example, the agreement will be extended to 95 countries around the world, but it still does not include Brazil, China, and Russia, which have seen an increase in cases in recent weeks.
Both have produced their own COVID-19 vaccines and have been vying to provide their own supplies to other countries. despite this, China with Russia A limited blockade has recently been restored to curb the increase in cases within its borders. Brazil The country with the highest number of deaths from COVID-19 in the world, second only to the United States.
Pfizer also agreed not to charge royalties for sales in low-income countries, and as long as Covid-19 remains a public health emergency, it will waive sales royalties in all countries/regions covered by the agreement.
November 5th, Pfizer Announce Clinical trials of its pill for the treatment of COVID-19 have shown that it is very effective, achieving a so-called 89% reduction in the risk of adult hospitalization and death.
It has not yet received regulatory approval in the United States or elsewhere, but has been hailed as an important achievement that can expand efforts to fight the COVID-19 pandemic.
Pfizer is not the only country that produces antiviral pills to treat the virus.Merck has also developed an antiviral pill Agree with Used from the UK.Swiss headquarters Roche It also announced that it was also studying its own pills, but encountered a trap in the process.
